Latest News

August 28, 2024

Attention radiation oncologists and trainees: Travel funds are available for the Fall 2024 Group Meeting (apply now)

August 21, 2024

How a patient’s role in a clinical trial for acute lymphocytic leukemia brought a cancer-free diagnosis, FDA approval

August 21, 2024

The implications of the E3311 trial in HPV+ head and neck cancer: Dr. Ranee Mehra

August 20, 2024

Blinatumomab improves 3-year overall survival in B-ALL versus chemotherapy (study E1910)

August 17, 2024

Nivolumab’s role in esophageal cancer neoadjuvant therapy: Dr. Jennifer Eads (study EA2174)

August 14, 2024

The August 2024 News from ECOG-ACRIN blog is now available

August 1, 2024

Advocate Health Care and Aurora Health Care cancer clinics join the EAQ211 trial, which seeks to determine why young lymphoma survivors are at high risk for other health problems

July 24, 2024

Press Release: New England Journal of Medicine publishes practice-changing E1910 trial results

July 9, 2024

ECOG-ACRIN research advocate and prostate cancer survivor Brian Jones is profiled in Cancer Today


About Us

The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1300 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More


Home

Scientific Pursuits

We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More


ECOG-ACRIN by the Numbers

Home
42

Active Clinical Trials

Home
1400

Participating Institutions

Home
67

International Sites

Home
21000

Individual Members


Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).

ECOG-ACRIN Cancer Research Group